Patents by Inventor Astrid Zimmermann

Astrid Zimmermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20230272083
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L antibody and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 expression.
    Type: Application
    Filed: December 23, 2022
    Publication date: August 31, 2023
    Inventors: Astrid ZIMMERMANN, Lars DAMSTRUP, Anne-Kathrin PROKEIN, Andreas SCHROEDER
  • HIGH REDUCTION RATIO TRANSMISSION
    Publication number: 20220316573
    Abstract: The present disclosure relates to a transmission having a ring gear in which a flexible gearwheel is arranged, where the flexible gearwheel is connected to a wave generator and the wave generator deforms the flexible gearwheel such that it is in engagement in some regions with the ring gear. The flexible gearwheel includes at least two toothed segments which are connected to one another by way of spring segments and at least one of the toothed segments includes a recess in which a pin element is arranged.
    Type: Application
    Filed: August 12, 2020
    Publication date: October 6, 2022
    Applicant: Maxon International AG
    Inventors: Ernst VON LEHMANN, Astrid ZIMMERMANN
  • COMBINATION OF A PD-1 ANTAGONIST, AN ATR INHIBITOR AND A PLATINATING AGENT FOR THE TREATMENT OF CANCER
    Publication number: 20220048997
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 17, 2022
    Inventors: Marat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
  • Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
    Patent number: 11246929
    Abstract: Combination therapy for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: February 15, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Damstrup, Thomas Grombacher, Christian Sirrenberg, Lyubomir Vassilev, Astrid Zimmermann
  • COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS
    Publication number: 20210369705
    Abstract: The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors.
    Type: Application
    Filed: October 14, 2019
    Publication date: December 2, 2021
    Applicant: Merck Patent GmbH
    Inventors: Carl DEUTSCH, Birgit PIATER, Nicolas RASCHE, Heike DAHMEN, Frank ZENKE, Astrid ZIMMERMANN, Marcel RIEKER
  • COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT
    Publication number: 20210353614
    Abstract: The present invention relates to compounds that can be used to induce immunogenic cell death (ICD). In some instances, two or more compounds are combined to induce ICD. The invention also relates to the combination of ICD-inducing compounds with an agent stimulating the immune system, such as an immune checkpoint inhibitor, in particular, to 5 treat cancer or inhibit tumor growth.
    Type: Application
    Filed: March 13, 2019
    Publication date: November 18, 2021
    Inventors: Astrid Zimmermann, Maria Jesus Ortiz Ruiz, Heike Dahmen, Thomas Grombacher
  • COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20200048352
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises an anti-PD-L antibody and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 expression.
    Type: Application
    Filed: March 27, 2018
    Publication date: February 13, 2020
    Inventors: Astrid Zimmermann, Lars Damstrup, Anne-Kathrin Prokein, Andreas Schroeder
  • COMBINATION OF A PROTEIN KINASE INHIBITOR AND AN ADDITIONAL CHEMOTHERAPEUTIC AGENT
    Publication number: 20190365896
    Abstract: Combination therapy for the treatment of cancer.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Inventors: Lars Damstrup, Thomas Grombacher, Christian Sirrenberg, Lyubomir Vassilev, Astrid Zimmermann
  • Substituted imidazoquinolines
    Patent number: 9908880
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 6, 2018
    Assignee: 4SC AG
    Inventors: Volker Gekeler, Thomas Maier, Astrid Zimmermann, Hans-Peter Hofmann, Sanjeev A. Kulkarni, Anil P. Jagtap, Ganesh S. Chaure
  • NOVEL SUBSTITUTED IMIDAZOQUINOLINES
    Publication number: 20170029422
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Application
    Filed: September 19, 2016
    Publication date: February 2, 2017
    Applicant: 4SC AG
    Inventors: Volker GEKELER, Thomas MAIER, Astrid ZIMMERMANN, Hans-Peter HOFMANN, Sanjeev A. KULKARNI, Anil P. JAGTAP, Ganesh S. CHAURE
  • Substituted imidazoquinolines
    Patent number: 9446040
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 20, 2016
    Assignee: 4SC AG
    Inventors: Volker Gekeler, Thomas Maier, Astrid Zimmermann, Hans-Peter Hofmann, Sanjeev A. Kulkarni, Anil P. Jagtap, Ganesh S. Chaure
  • GENE EXPRESSION BIOMARKERS AND THEIR USE FOR DIAGNOSTIC AND PROGNOSTIC APPLICATION IN PATIENTS POTENTIALLY IN NEED OF HDAC INHIBITOR TREATMENT
    Publication number: 20160215348
    Abstract: The present invention relates to the utilization of one or more genes selected from the group comprising ZFP64, DPP3, CCDC43, HIST2H4A/B, KDELC2 and MICALL1 as biomarkers for HDAC inhibitor treatment. The expression and/or change of the aforementioned genes are preferably determined via the respective corresponding mRNA or one or more proteins expressed by the aforementioned genes.
    Type: Application
    Filed: May 22, 2014
    Publication date: July 28, 2016
    Applicant: 4SC AG
    Inventors: Hella KOHLHOF, Thomas HERZ, Robert DOBLHOFER, Thomas BECKERS (Deceased), Astrid ZIMMERMANN, Marina MOLLENHAUER-THEIN, Markus BOEHM, Volker GEKELER, Hans-Peter HOFMANN, Thomas MAIER, Eike STAUB, Timo WITTENBERGER, Martin ELMLINGER
  • Fused bicyclic imidazoles
    Patent number: 9387204
    Abstract: Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: July 12, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Swen Hölder, Armin Zülch, Thomas Bär, Thomas Maier, Astrid Zimmermann, Thomas Beckers, Volker Gekeler, Hemant Joshi, Yogesh Munot, Umesh Bhise, Sunil Chavan, Sachin Shivatare, Sarvesh Patel, Vikas Gore
  • NOVEL SUBSTITUTED IMIDAZOQUINOLINES
    Publication number: 20150335636
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Application
    Filed: June 3, 2015
    Publication date: November 26, 2015
    Applicant: 4SC AG
    Inventors: Volker GEKELER, Thomas MAIER, Astrid ZIMMERMANN, Hans-Peter HOFMANN, Sanjeev A. KULKARNI, Anil P. JAGTAP, Ganesh S. CHAURE
  • Substituted imidazoquinolines
    Patent number: 9073913
    Abstract: Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: July 7, 2015
    Assignee: 4SC AG
    Inventors: Volker Gekeler, Thomas Maier, Astrid Zimmermann, Hans-Peter Hofmann, Sanjeev A. Kulkarni, Anil P. Jagtap, Ganesh S. Chaure
  • N-sulphonylpyrroles and their use as histone deacetylase inhibitors
    Patent number: 8815855
    Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: August 26, 2014
    Assignee: 4SC AG
    Inventors: Thomas Maier, Thomas Bär, Thomas Beckers, Astrid Zimmermann, Siegfried Schneider, Volker Gekeler
  • FUSED BICYCLIC IMIDAZOLES
    Publication number: 20140088110
    Abstract: Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.
    Type: Application
    Filed: November 26, 2013
    Publication date: March 27, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GmbH
    Inventors: Swen HÖLDER, Armin ZÜLCH, Thomas BÄR, Thomas MAIER, Astrid ZIMMERMANN, Thomas BECKERS, Volker GEKELER, Hemant JOSHI, Yogesh MUNOT, Umesh BHISE, Sunil CHAVAN, Sachin SHIVATARE, Sarvesh PATEL, Vikas GORE
  • Fused bicyclic pyrimidines
    Patent number: 8614218
    Abstract: Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: December 24, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Swen Hölder, Matthias Vennemann, Gerrit Beneke, Armin Zülch, Volker Gekeler, Thomas Beckers, Astrid Zimmermann, Hemant Joshi
  • Fused bicyclic imidazoles
    Patent number: 8592591
    Abstract: Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: November 26, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Swen Hölder, Armin Zülch, Thomas Bär, Thomas Maier, Astrid Zimmermann, Thomas Beckers, Volker Gekeler, Hemant Joshi, Yogesh Munot, Umesh Bhise, Sunil Chavan, Sachin Shivatare, Sarvesh Patel, Vikas Gore
  • Indolopyridines as Eg5 kinesin modulators
    Patent number: 8530493
    Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: September 10, 2013
    Assignee: 4SC AG
    Inventors: Matthias Vennemann, Thomas Bãr, Jürgen Braunger, Astrid Zimmermann, Volker Gekeler